Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Is Abbott Laboratories Stock Underperforming the Dow?

May 29, 2026 at 07:30 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Illinois-based Abbott Laboratories (ABT) is a diversified healthcare company that develops and manufactures medical devices, diagnostics, nutritional products, and branded generic medicines. Valued at $149.2 billion by market cap, it operates in more than 160 countries and is one of the world's largest healthcare companies.

Companies worth $10 billion or more are generally described as “large-cap stocks,” and ABT definitely fits that description, with its market cap exceeding this threshold, reflecting its substantial size, influence, and dominance in the medical devices industry.

More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.

Despite its notable strength, ABT slipped 37.9% from its 52-week high of $139.06, achieved on June 24, 2025. Over the past three months, ABT stock declined 25.8%, trailing the Dow Jones Industrial Average’s ($DOWI) 3.5% rise during the same time frame.

Shares of ABT fell 31.1% on a YTD basis and dipped 34.6% over the past 52 weeks, underperforming DOWI’s 5.4% YTD rise and solid 20.4% returns over the last year.

To confirm the bearish trend, ABT has been trading below its 50-day and 200-day moving averages since mid-October 2025.

Abbott Laboratories has lagged the broader market over the past year as investors grappled with slowing growth in its diagnostics and nutrition businesses, including continued normalization of COVID-related testing demand, softer sales of rapid diagnostic products, and weakness in infant nutrition. Sentiment was further pressured by concerns over slower-than-expected growth in its FreeStyle Libre diabetes franchise, acquisition-related earnings dilution, and several earnings reports that fell short of market expectations.

In the competitive arena of medical devices, Boston Scientific Corporation (BSX) has lagged behind ABT, with a 53% downtick over the past 52 weeks and a 48.5% loss on a YTD basis.

Wall Street analysts are bullish on ABT’s prospects. The stock has a consensus “Strong Buy” rating from the 28 analysts covering it, and the mean price target of $118.67 suggests a potential upside of 37.5% from current price levels.

On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.

More news from Barchart

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article